Clinical trials: Inhalation
Anesthesia
Ambu AuraGain and Teleflex LMA Protector Fiberoptic Assessments in Elective Patients
Participant is being asked to take part in this study because participant is going to have surgery that requires general anesthesia (in which participant is unconscious for the procedure).
- Trial name
- NCT02724956
- Testing
- Ambu AuraGain, Teleflex LMA Protector, Ambu aScope
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Sleep Apnea Syndromes, Sleep Disorder
WatchPAT Device Validation Study Compared to Polysomnography
Validation study of a novel sleep Device compared to a traditional sleep study.
- Conditions
- Sleep Apnea Syndromes, Sleep Disorder, Sleep
- Trial name
- WPAT (NCT03188718)
- Testing
- WatchPAT Intervention
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Sickle Cell Disease
Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease
The proposed research is designed to test the global hypothesis that inhaled corticosteroids (ICS), a therapy developed to treat asthma, will prevent vasoocclusive painful episodes in adults with Sickle Cell Disease (SCD) who…
- Trial name
- IMPROVE (NCT02061202)
- Testing
- Mometasone Furoate
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Jeffrey Glassberg
Cardiac Arrest, Sudden Cardiac Death
Hemodynamic Effects of Standard Cardiopulmonary Resuscitation (CPR), Active Compression Decompression CPR With an Inspiratory Impedance Device, and Standard CPR With an Intrathoracic Pressure Regulator During Out-of-hospital Cardiac Arrest
More than 300,000 Americans experience out-of-hospital cardiac arrest annually, with overall survival rates averaging less than 5%.
- Trial name
- NCT01325870
- Testing
- ACD-CPR, ITPR, S-CPR
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Advanced Circulatory Systems
Paroxysmal Atrial Fibrillation (PAF)
INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT)
The study consisted of 3 parts (Part A, Part B and Part C). Part A was an open-label, randomized, multi center design to evaluate the feasibility of administration of inhaled flecainide in two dosing regimens.
- Trial name
- INSTANT (NCT03539302)
- Testing
- Flecainide Acetate
- Where
- 9 sites in Belgium, Netherlands
- Volunteers
- 176 people
- Sponsor
- InCarda Therapeutics, Inc.
Preeclampsia, Hypertension
Study of Positive Airway Pressure in Preeclampsia to Reduce Blood Pressure
The purpose of this study is to identify whether sleep-disordered breathing - as measured by overnight polysomnography - is associated with pre-eclampsia and to determine whether use of positive airway pressure can improve…
- Trial name
- NCT01029691
- Testing
- Positive Airway Pressure
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- University of Michigan
Abuse Liability of Staccato Alprazolam
Staccato Alprazolam Abuse Liability
Compare the abuse liabilities of Staccato Alprazolam, oral immediate-release alprazolam, and Staccato Placebo.
- Trial name
- NCT00603980
- Testing
- Inhaled alprazolam 0.5 mg, Inhaled alprazolam 1 mg, Inhaled alprazolam 2 mg
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Nova Pneuma Inc.
Depression, Postpartum, Anxiety Disorders
Inhaled Oxytocin and HPA Axis Reactivity
Mothers who were enrolled in the Mood, Mother and Infant study will be eligible to participate in the 6-year follow-up maternal visit.
- Conditions
- Depression, Postpartum, Anxiety Disorders, Stress, Psychological
- Trial name
- NCT03593473
- Testing
- Intranasal Oxytocin
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- University of North Carolina, Chapel Hill
Asthma
Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).
The aim of the study is to assess and compare efficacy and safety of BI 54903 at three different dosages (b.i.d)., fluticasone propionate hydrofluoroalkane (HFA) metered dose inhaler (MDI) at a dose of 440 mcg b.i.d and low dose…
- Trial name
- NCT01396278
- Testing
- Fluticasone propionate, BI 54903
- Where
- 37 sites in United States
- Volunteers
- 9 people
- Sponsor
- Boehringer Ingelheim
Persistent Asthma
Study of Safety of Foradil in Patients With Persistent Asthma
The purpose of this study was to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, asthma related intubations, and asthma related deaths) in adolescents and adults (12 years of age and…
- Trial name
- NCT01845025
- Testing
- Formoterol 12 mcg, Fluticasone propionate 100 mcg, Fluticasone propionate 250 mcg
- Where
- 27 sites in United States
- Volunteers
- 827 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Sleep Disordered Breathing
Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure
The purpose of this trial is to evaluate the long-term effects and cost-effectiveness of adaptive servo-ventilation (ASV) on the mortality and morbidity of patients with stable heart failure due to left ventricular systolic…
- Trial name
- Serve-HF (NCT00733343)
- Testing
- Europe: AutoSet CS (USA: VPAP Adapt SV)
- Where
- 267 sites in Australia, Czechia and 9 more
- Volunteers
- 1,325 people
- Sponsor
- ResMed
Asthma
Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans
To compare the efficacy of SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily (bid) to that of budesonide inhalation powder DPI 180 μg x 2 inhalations bid, in African American(self-reported) subjects with inhaled…
- Trial name
- Titan (NCT00702325)
- Testing
- Budesonide / formoterol fumarate (SYMBICORT), Budesonide
- Where
- 57 sites in United States
- Volunteers
- 311 people
- Sponsor
- AstraZeneca
Sore-throat, Dysphonia
No Post Intubation Laryngeal Symptoms
The purpose of the study is to test a novel endotracheal tube support device that reduces pressure of the tube on the voice box for prevention of post intubation laryngeal symptoms including sore throat, change in voice and…
- Conditions
- Sore-throat, Dysphonia, Dysphagia, Intubation Complication
- Trial name
- No-PILS (NCT05383417)
- Testing
- EndoClip
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Pulmonary Disease, Chronic Obstructive
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period.
- Trial name
- NCT01040689
- Testing
- Olodaterol (BI1744) Low, Olodaterol (BI1744) High, Tiotropium 18 mcg
- Where
- 15 sites in Belgium, Denmark and 2 more
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
The purpose of the study is to determine the efficacy and safety of the combination of ADVAIR DISKUS® 250/50mcg (FLUTICASONE PROPIONATE/SALMETEROL COMBINATION PRODUCT) plus SPIRIVA® HANDIHALER® inhaler 18mcg (TIOTROPIUM) compared…
- Trial name
- ADC111114 (NCT00784550)
- Testing
- Tiotropium Bromide, Fluticasone Propionate/Salmeterol
- Where
- 35 sites in United States
- Volunteers
- 342 people
- Sponsor
- GlaxoSmithKline
Autoimmune Pulmonary Alveolar Proteinosis
Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim (MOL) or placebo (PBO) for 48 weeks.
- Trial name
- IMPALA-2 (NCT04544293)
- Testing
- Molgramostim, Molgramostim Open-label
- Where
- 54 sites in United States, Australia and 16 more
- Volunteers
- 164 people
- Sponsor
- Savara Inc.
Patients With Schizophrenia and Acute Agitation
Staccato Loxapine in Agitated Patients With Schizophrenia
Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in schizophrenic patients
- Trial name
- NCT00628589
- Testing
- Inhaled loxapine 5 mg, Inhaled loxapine 10 mg
- Where
- United States
- Volunteers
- 344 people
- Sponsor
- Alexza Pharmaceuticals, Inc.
Bronchopulmonary Dysplasia
Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia
The purpose of this study is to determine if late doses of Infasurf surfactant given when patients are receiving inhaled nitric oxide will interact to improve surfactant function and increase survival without BPD in treated…
- Trial name
- TOLSURF (NCT01022580)
- Testing
- Infasurf surfactant (ONY, Inc.)
- Where
- 21 sites in United States
- Volunteers
- 511 people
- Sponsor
- Roberta Ballard
Asthma
Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma
An unmet medical need exists for patients with moderate and severe asthma who continue to demonstrate symptoms despite being on standard of care medications, and are not eligible for other biologic therapies developed or in…
- Trial name
- NCT03299686
- Testing
- CJM112
- Where
- 29 sites in United States, Argentina and 6 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Hypertension, Heart Failure, Diastolic
Inhaled Nitrite in Subjects With Pulmonary Hypertension
This is a single-center, open label phase II study to evaluate the effect of inhaled nitrite delivered in a dose escalation manner on the change in pulmonary vascular resistance (PVR) in subjects with pulmonary hypertension…
- Trial name
- NCT01431313
- Testing
- Inhaled Nitrite
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Schmidhofer, Mark, MD